Based on the Accuray Incorporated stock forecast from 3 analysts, the average analyst target price for Accuray Incorporated is USD 6.25 over the next 12 months. Accuray Incorporated’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Accuray Incorporated is Bearish, which is based on 3 positive signals and 8 negative signals. At the last closing, Accuray Incorporated’s stock price was USD 1.52. Accuray Incorporated’s stock price has changed by +1.33% over the past week, -18.28% over the past month and -29.95% over the last year.
No recent analyst target price found for Accuray Incorporated
No recent average analyst rating found for Accuray Incorporated
Company Overview Accuray Incorporated
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin. Read Less
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers th...Read More
Frequently Asked Questions About Accuray Incorporated (ARAY) Stock
Based on ratings from 3 analysts Accuray Incorporated's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARAY's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ARAY is USD 6.25 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 6.
ARAY stock's Price/Earning ratio is 77.60.
Our analysis grades ARAY stock's Price / Earning ratio at F. This means that ARAY stock's Price/Earning ratio is above 82% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this ARAY may be a overvalued for its sector.
The last closing price of ARAY's stock was USD 1.52.
The most recent market capitalization for ARAY is USD 0.16B.
Based on targets from 3 analysts, the average taret price for ARAY is projected at USD 6.25 over the next 12 months.
This means that ARAY's stock price may go up by +311.18% over the next 12 months.
We can't find any ETFs which contains Accuray Incorporated's stock.
As per our most recent records Accuray Incorporated has 987 Employees.
Accuray Incorporated's registered address is 1240 Deming Way, Madison, WI, United States, 53717-1954.
You can get more information about it from Accuray Incorporated's website at https://www.accuray.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Accuray Incorporated (ARAY) Stock
Based on ratings from 3 analysts Accuray Incorporated's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARAY's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ARAY is USD 6.25 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 6.
ARAY stock's Price/Earning ratio is 77.60.
Our analysis grades ARAY stock's Price / Earning ratio at F. This means that ARAY stock's Price/Earning ratio is above 82% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this ARAY may be a overvalued for its sector.
The last closing price of ARAY's stock was USD 1.52.
The most recent market capitalization for ARAY is USD 0.16B.
Based on targets from 3 analysts, the average taret price for ARAY is projected at USD 6.25 over the next 12 months.
This means that ARAY's stock price may go up by +311.18% over the next 12 months.
We can't find any ETFs which contains Accuray Incorporated's stock.
As per our most recent records Accuray Incorporated has 987 Employees.
Accuray Incorporated's registered address is 1240 Deming Way, Madison, WI, United States, 53717-1954.
You can get more information about it from Accuray Incorporated's website at https://www.accuray.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARAY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
